$EMED
Electromedical Technologies, Inc Stock $emed

$emed Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000141057823000555 Filed on March 31, 2023

Income Statement

Concept	2022 Q4	2022
Revenue	$423.2K	$1.150M
YoY Change	78.69%	26.72%
Cost Of Revenue	$90.22K	$261.2K
YoY Change	119.14%	31.1%
Gross Profit	$332.9K	$888.6K
YoY Change	70.17%	25.49%
Gross Profit Margin	78.68%	77.28%
Selling, General & Admin	$584.8K	$2.492M
YoY Change	-65.2%	-44.72%
% of Gross Profit	175.65%	280.45%
Research & Development		$92.30K
YoY Change		-57.13%
% of Gross Profit		10.39%
Depreciation & Amortization	$5.470K	$21.88K
YoY Change	0.0%	0.0%
% of Gross Profit	1.64%	2.46%
Operating Expenses	$590.3K	$2.584M
YoY Change	-64.99%	-45.29%
Operating Profit	-$257.3K	-$1.604M
YoY Change	-82.74%	-57.8%
Interest Expense	-$280.7K	$791.1K
YoY Change	-20.93%	-76.13%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.865M
YoY Change		-60.15%
Pretax Income	-$830.1K	-$3.469M
YoY Change	-55.02%	-59.1%
Income Tax
% Of Pretax Income
Net Earnings	-$854.8K	-$3.469M
YoY Change	-53.68%	-59.1%
Net Earnings / Revenue	-202.01%	-301.65%
Basic Earnings Per Share		-$0.03
Diluted Earnings Per Share	$0.00	-$0.03
COMMON SHARES
Basic Shares Outstanding	172.9M	133.6M
Diluted Shares Outstanding		133.6M

Balance Sheet

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$368.4K	$368.4K
YoY Change	-3.85%	-3.85%
Cash & Equivalents	$368.4K	$368.4K
Short-Term Investments
Other Short-Term Assets	$207.9K	$207.9K
YoY Change	447.03%	447.03%
Inventory	$62.06K	$62.06K
Prepaid Expenses
Receivables	$9.444K	$9.440K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$647.8K	$647.8K
YoY Change	-4.0%	-4.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$705.5K	$705.5K
YoY Change	-3.01%	-3.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$705.5K	$705.5K
YoY Change	-3.01%	-3.01%
TOTAL ASSETS
Total Short-Term Assets	$647.8K	$647.8K
Total Long-Term Assets	$705.5K	$705.5K
Total Assets	$1.353M	$1.353M
YoY Change	-3.48%	-3.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$266.7K	$304.4K
YoY Change	24.19%	34.64%
Accrued Expenses	$193.8K	$1.065M
YoY Change	-38.86%	236.07%
Deferred Revenue	$217.6K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.337M	$1.337M
YoY Change	48.68%	48.68%
Total Short-Term Liabilities	$2.924M	$2.924M
YoY Change	102.76%	102.76%
LONG-TERM LIABILITIES
Long-Term Debt	$639.7K	$639.7K
YoY Change	-4.99%	-4.99%
Other Long-Term Liabilities	$10.23K	$10.23K
YoY Change	11.64%	11.56%
Total Long-Term Liabilities	$10.23K	$649.9K
YoY Change	11.64%	-4.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.924M	$2.924M
Total Long-Term Liabilities	$10.23K	$649.9K
Total Liabilities	$3.574M	$3.574M
YoY Change	68.22%	68.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.83M
YoY Change	13.45%
Common Stock	$1.896K
YoY Change	116.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.221M	-$2.221M
YoY Change
Total Liabilities & Shareholders Equity	$1.353M	$1.353M
YoY Change	-3.48%	-3.48%

Cashflow Statement

Concept	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$854.8K	-$3.469M
YoY Change	-53.68%	-59.1%
Depreciation, Depletion And Amortization	$5.470K	$21.88K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$33.10K	-$773.3K
YoY Change	-88.49%	-35.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$42.77K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-57.39K	758.6K
YoY Change	-111.34%	-42.18%
NET CHANGE
Cash From Operating Activities	-33.10K	-773.3K
Cash From Investing Activities
Cash From Financing Activities	-57.39K	758.6K
Net Change In Cash	-90.49K	-14.75K
YoY Change	-141.44%	-112.47%
FREE CASH FLOW
Cash From Operating Activities	-$33.10K	-$773.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001715819
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217588
CY2021	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://electromedtech.com/20221231#ChangeInFairValueOfDerivativeLiabilities
CY2022Q2	elcq	Debt Instrument Debt Default Extension Of Maturity Term DebtInstrumentDebtDefaultExtensionOfMaturityTerm	P5Y
CY2021	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://electromedtech.com/20221231#ChangeInFairValueOfDerivativeLiabilities
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-56192
CY2022	dei	Entity Registrant Name EntityRegistrantName	ELECTROMEDICAL TECHNOLOGIES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2619815
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	16561 N. 92nd Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 101
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Scottsdale
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85260
CY2022	dei	City Area Code CityAreaCode	888
CY2022	dei	Local Phone Number LocalPhoneNumber	880-7888
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87725842
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1896
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	876
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	1328492
CY2022	dei	Auditor Name AuditorName	dbbmckennon
CY2022	dei	Auditor Firm AuditorFirmId	3501
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	368425
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	383170
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9444
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35085
CY2022Q4	us-gaap	Inventory Net InventoryNet	62061
CY2021Q4	us-gaap	Inventory Net InventoryNet	218510
CY2022Q4	elcq	Prepaid Inventories And Other Current Assets PrepaidInventoriesAndOtherCurrentAssets	207872
CY2021Q4	elcq	Prepaid Inventories And Other Current Assets PrepaidInventoriesAndOtherCurrentAssets	38002
CY2022Q4	us-gaap	Assets Current AssetsCurrent	647802
CY2021Q4	us-gaap	Assets Current AssetsCurrent	674767
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	705469
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2022Q4	us-gaap	Assets Assets	1353271
CY2021Q4	us-gaap	Assets Assets	1402111
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	266744
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	214785
CY2022Q4	elcq	Credit Cards Payable CreditCardsPayable	37633
CY2021Q4	elcq	Credit Cards Payable CreditCardsPayable	11283
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1065483
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	317037
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217588
CY2022Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	375865
CY2021Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	723166
CY2022Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	1304909
CY2021Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	811687
CY2021Q4	elcq	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	57875
CY2022Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	31818
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	29502
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2924175
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1442169
CY2022Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	489707
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	518849
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	150000
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	154429
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10234
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9167
CY2022Q4	us-gaap	Liabilities Liabilities	3574116
CY2021Q4	us-gaap	Liabilities Liabilities	2124614
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	999000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189784529
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22237300
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20804333
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24825041
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21882712
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2220845
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1353271
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1402111
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1149844
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	907362
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	261203
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	199234
CY2022	us-gaap	Gross Profit GrossProfit	888641
CY2021	us-gaap	Gross Profit GrossProfit	708128
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2492169
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4508391
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1603528
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3800263
CY2022	us-gaap	Interest Expense InterestExpense	791072
CY2021	us-gaap	Interest Expense InterestExpense	3313852
CY2021	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1415685
CY2021	elcq	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-432
CY2022	elcq	Debt Instrument Forgiveness Of Debt DebtInstrumentForgivenessOfDebt	-5900
CY2021	elcq	Debt Instrument Forgiveness Of Debt DebtInstrumentForgivenessOfDebt	-50083
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1079800
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1864972
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4679886
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3468500
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8480149
CY2022	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	107888
CY2021	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	3770831
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3576388
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12250980
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133596295
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133596295
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50992414
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50992414
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1318603
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	906226
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	57191
CY2021	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	1095096
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5226074
CY2021	elcq	Stock Issued During Period Value Conversion Of Convertible Note And Notes Payable StockIssuedDuringPeriodValueConversionOfConvertibleNoteAndNotesPayable	124935
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-1666727
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8480149
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42766
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	494900
CY2022	elcq	Stock Issued During Period Value In Conjunction Forbearance Of Convertible Debt StockIssuedDuringPeriodValueInConjunctionForbearanceOfConvertibleDebt	142800
CY2022	elcq	Share Issued During Period Value Convertible Promissory Notes Settlement ShareIssuedDuringPeriodValueConvertiblePromissoryNotesSettlement	708370
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14745
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	118257
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	383170
CY2022	elcq	Adjustments To Additional Paid In Capital Warrant Issued In Conjunction With Debt Settlement AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConjunctionWithDebtSettlement	65000
CY2022	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	445974
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	435000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14703
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3468500
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2220845
CY2022	us-gaap	Profit Loss ProfitLoss	-3468500
CY2021	us-gaap	Profit Loss ProfitLoss	-8480149
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	509603
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2630144
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2022	elcq	Forgiveness Of Debt Instrument ForgivenessOfDebtInstrument	5900
CY2021	elcq	Forgiveness Of Debt Instrument ForgivenessOfDebtInstrument	50083
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1079800
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	584261
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3036792
CY2021	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1415685
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2839
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25641
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17391
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-156449
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	139798
CY2022	elcq	Prepaid Inventories And Other Current Asset PrepaidInventoriesAndOtherCurrentAsset	169870
CY2021	elcq	Prepaid Inventories And Other Current Asset PrepaidInventoriesAndOtherCurrentAsset	-285860
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	17401
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51959
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40529
CY2022	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	26350
CY2021	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	-12427
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	196340
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	205982
CY2022	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	217588
CY2021	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	-28651
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1067
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-6436
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-773337
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1193688
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	25355
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	26334
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-57875
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-158875
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1545140
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1510000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	746084
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12846
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42766
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	758592
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1311945
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264913
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	368425
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	383170
CY2022	us-gaap	Interest Paid Net InterestPaidNet	103819
CY2021	us-gaap	Interest Paid Net InterestPaidNet	154081
CY2022	elcq	Adoption Of Accounting Standard AdoptionOfAccountingStandard	379355
CY2022	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	510974
CY2021	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	1095096
CY2021	elcq	Derivative Liabilities Issued In Conjunction With Convertible Promissory Notes DerivativeLiabilitiesIssuedInConjunctionWithConvertiblePromissoryNotes	1197607
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1103370
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5223235
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities, certain disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates affecting the financial statements have been prepared on the basis of the most current and best available information. However, actual results from the resolution of such estimates and assumptions may vary from those used in the preparation of the financial statements.</p>
CY2022	elcq	Accumulated Net Loss AccumulatedNetLoss	21100000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-773337
CY2022	elcq	Working Capital Deficit WorkingCapitalDeficit	2300000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	880340
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	132945
CY2022	elcq	Right Of Return Period RightOfReturnPeriod	P30D
CY2021	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2022	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217588
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2022	elcq	Initial Warranty Period InitialWarrantyPeriod	P3Y
CY2022Q4	us-gaap	Deferred Income DeferredIncome	23313
CY2021Q4	us-gaap	Deferred Income DeferredIncome	28252
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1000
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	14047
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	13900
CY2022Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	0
CY2021Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	12800
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	747395
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	831852
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1415685
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1197607
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-3445144
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	933627
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193848
CY2022Q4	elcq	Deferred Tax Accounts Payable DeferredTaxAccountsPayable	13457
CY2022Q4	elcq	Deferred Tax Assets Customer Deposits DeferredTaxAssetsCustomerDeposits	56355
CY2022	elcq	Effective Income Tax Rate Reconciliation Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationFederalStatutoryIncomeTaxRate	0.259
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.259
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	53288
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	333084
CY2022	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	214257
CY2021	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	1339245
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	39500
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4090409
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3876152
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2022	elcq	Standard Warranty Period StandardWarrantyPeriod	P3Y
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	12679
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	14828
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92299
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	215320
CY2022Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	231796422
CY2021Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	32883205
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	194518
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	172643
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	705469
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	158875
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	57875
CY2022	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	78
CY2021	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	18590
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.025
CY2022Q2	elcq	Number Of Warrants Issued NumberOfWarrantsIssued	2500000
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1680774
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	375865
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2022Q4	us-gaap	Notes Payable NotesPayable	1304909
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2022Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	78495
CY2022Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	95410
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1680774
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	375865
CY2022Q4	us-gaap	Notes Payable NotesPayable	1304909
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	31490
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	30586
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	459449
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1675
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	148325
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	671525
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	831852
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1415685
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1197607
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-3445144
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	158875
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	57875
CY2022	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	78
CY2021	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	18590
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7500000
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2200000
CY2022	us-gaap	Stock Issued1 StockIssued1	262500
CY2021	us-gaap	Stock Issued1 StockIssued1	550000
CY2022Q2	elcq	Debt Conversion Converted Instrument Accrued Interest Amount DebtConversionConvertedInstrumentAccruedInterestAmount	51017
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	26734801
CY2022	elcq	Cashless Warrants Exercised CashlessWarrantsExercised	17249999
CY2022	elcq	Number Of Shares Issued Upon Exercise Of Warrants NumberOfSharesIssuedUponExerciseOfWarrants	13264887
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	350000
CY2022	elcq	Stock Issued During Period Shares Conversion Of Convertible Note And Notes Payable StockIssuedDuringPeriodSharesConversionOfConvertibleNoteAndNotesPayable	30500000
CY2021Q4	us-gaap	Share Price SharePrice	0.5499
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1699800
CY2021	elcq	Debt Conversion Converted Instrument Accrued Interest Amount DebtConversionConvertedInstrumentAccruedInterestAmount	49334051
CY2022Q3	us-gaap	Share Price SharePrice	0.02
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	50000000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	3000000
CY2022	elcq	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued Price Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedPricePerShare	0.01
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	21000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21807
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	445000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0
CY2022	elcq	Warrants Issued WarrantsIssued	21000000
CY2022Q4	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	385422
CY2022Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	500000
CY2022Q2	elcq	Warrants Issued WarrantsIssued	2500000
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	65000
CY2022Q2	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	65000
CY2022Q2	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	259000
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27837533
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.446
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0093
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18468499
CY2021	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	3770831
CY2022	elcq	Commitment For Product Development CommitmentForProductDevelopment	525000
CY2022	elcq	Amount For Commitment For Product Development Paid AmountForCommitmentForProductDevelopmentPaid	212000

Files In Submission

Name	View Source	Status
elcq-20221231_cal.xml	Edgar Link	unprocessable
elcq-20221231_def.xml	Edgar Link	unprocessable
0001410578-23-000555-index-headers.html	Edgar Link	pending
0001410578-23-000555-index.html	Edgar Link	pending
0001410578-23-000555.txt	Edgar Link	pending
0001410578-23-000555-xbrl.zip	Edgar Link	pending
elcq-20221231.xsd	Edgar Link	pending
elcq-20221231x10k.htm	Edgar Link	pending
elcq-20221231x10k001.jpg	Edgar Link	pending
elcq-20221231xex10d10.htm	Edgar Link	pending
elcq-20221231xex10d11.htm	Edgar Link	pending
elcq-20221231xex10d12.htm	Edgar Link	pending
elcq-20221231xex10d13.htm	Edgar Link	pending
elcq-20221231xex10d4.htm	Edgar Link	pending
elcq-20221231xex10d5.htm	Edgar Link	pending
elcq-20221231xex10d6.htm	Edgar Link	pending
elcq-20221231xex10d7.htm	Edgar Link	pending
elcq-20221231xex10d8.htm	Edgar Link	pending
elcq-20221231xex10d8001.jpg	Edgar Link	pending
elcq-20221231xex10d9.htm	Edgar Link	pending
elcq-20221231xex31d1.htm	Edgar Link	pending
elcq-20221231xex31d2.htm	Edgar Link	pending
elcq-20221231xex32d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
elcq-20221231_lab.xml	Edgar Link	unprocessable
elcq-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elcq-20221231x10k_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMED
Electromedical Technologies, Inc Stock $emed

2022 Q4 Form 10-K Financial Statement

#000141057823000555 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED Electromedical Technologies, Inc Stock $emed

2022 Q4 Form 10-K Financial Statement

#000141057823000555 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED
Electromedical Technologies, Inc Stock $emed